Novocure receives CE mark for Optune Pax device

Novocure has received CE Mark for Optune Pax, its portable medical device intended to treat adults with locally advanced pancreatic cancer of exocrine origin. The decision was based on findings from the Phase III PANOVA-3 clinical trial. The PANOVA-3 trial enrolled 571 patients with locally advanced pancreatic cancer. Credit: sasirin pamai/Shutterstock.com. Novocure has received the CE mark for Optune Pax, its portable medical device intended to treat adults with locally advanced pancreatic cancer of exocrine origin. The device is intended to be used in combination with gemcitabine and nab-paclitaxel, as recommended by clinical guidelines. Combine business intelligence and editorial excellence…

Source: Medical Device Network